1Pfeffer K. Biological functions of tumor necrosis factor cytokines and their receptors [ J ]. Cytokine Growth Factor Rev,2003,14(3/4) :185-191.
2Roach DR, Briscoe H, Saunders B, et al. Secreted lymphotoxin - alpha is essential for the control of an intracellular bacterial infection[J]. J Exp Med, 2001,193 (2) : 239-246.
3Hehlgans T, Pfeffer K. The intriguing biology of the tumournecrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games[J]. Immunology, 2005,115(1):1-20.
5Sandborn WJ,Hanauer SB,Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial[J]. Gastroenterology,2001,121 (5) : 1088-1094.
6Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists [J]. J Pharmaeol Exp Ther,2002,301(2) :418-426.
7Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents [J]. Arthritis Rheum,2005,52(9) :3403-3412.
8Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists[J]. Clin Infect Dis, 2004,38 (9) : 1261-1265.
9Bergstrom L, Yoeum DE, Ampel NM, et al. Increased risk of eoecidioidomycosis in patients treated with tumor necrosis factor antagonists[J]. Arthritis Rheum, 2004, 50 (6) : 1959- 1966.
10Tubach F, Salmon-Ceron D, Ravaud P, et al. The RATIO observatory:French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti- TNFalpha therapy[J]. Joint Bone Spine, 2005,72(6) : 456-460.
